Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calprotectin and neutrophil gelatinase-associated lipocalin in the differentiation of pre-renal and intrinsic acute kidney injury.

Acta physiologica (Oxford, England)·2013
Same author

Country of origin predicts nutrition risk among community living older people.

The journal of nutrition, health & aging·2011
Same author

Therapeutic nursing care of orthopedic patients.

The Nursing clinics of North America·2010
Same author

Are ACE-inhibitors or ARB's still needed for cardiovascular prevention in high risk patients? Insights from profess and transcend.

Acta clinica Belgica·2010
Same author

Diagnostic value of confocal endomicroscopy in celiac disease.

Endoscopy·2010
Same author

Generics and cost-effective prescribing in Belgium: does bioequivalence always translate in therapeutic equivalence?

Acta clinica Belgica·2009
Same journal

MEFV variants as phenotypic modifiers in ankylosing spondylitis: a genetic interaction analysis with HLA-B27.

Acta clinica Belgica·2026
Same journal

What Europe should (not) learn from the new Dietary Guidelines for Americans.

Acta clinica Belgica·2026
Same journal

Real-world evidence on In-hospital statin use and mortality in geriatric patients.

Acta clinica Belgica·2026
Same journal

TKI-associated proteinuria and nephrotic syndrome: a narrative review with clinical illustration in radio-iodine-refractory thyroid cancer.

Acta clinica Belgica·2026
Same journal

A decade of insulin pump therapy in a Belgian paediatric diabetes centre: longitudinal outcomes and evolving practices.

Acta clinica Belgica·2026
Same journal

Pneumococcal vaccination in Belgian adults: a practical translation of the 2025 Superior Health Council guidelines.

Acta clinica Belgica·2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Genetics/genomics and drug effects.

F Heller1

  • 1Centre Hospitalier Jolimont-Lobbes, Haine St Paul, Belgium. frma.heller@skynet.be

Acta Clinica Belgica
|August 24, 2013
PubMed
Summary
This summary is machine-generated.

Genetic variations influence drug responses, affecting metabolism, transport, and targets. Pharmacogenetics and pharmacogenomics aim to personalize medicine, improving drug efficacy and safety for patients.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Experiment Videos

Last Updated: May 8, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Area of Science:

  • Pharmacogenetics and Pharmacogenomics
  • Genetics and Drug Response

Background:

  • Individual variability in drug response (efficacy and side effects) is a long-recognized clinical challenge.
  • Genetics is increasingly identified as a key factor influencing this inter-individual variability in drug response.

Purpose of the Study:

  • To explore the role of genetic variations in drug metabolism, transport, and targets.
  • To discuss the potential of pharmacogenetics and pharmacogenomics in personalizing medicine.

Main Methods:

  • Review of genetic polymorphisms affecting drug-metabolizing enzymes (e.g., Cytochrome P450s, phase II enzymes).
  • Examination of genetic influences on drug transporters and drug targets (e.g., tumor cells).
  • Discussion of current genetic testing applications (e.g., warfarin screening, oncology biomarkers).

Main Results:

  • Genetic polymorphisms in enzymes like CYPs (2D6, 2C9, 2C19) and phase II enzymes can alter drug metabolism, impacting responses to medications such as codeine, warfarin, and 5-fluorouracil.
  • Genetic variations can affect drug transporters and drug targets, influencing the efficacy of chemotherapy and statins.
  • Genetic tests are available for specific drug-associated polymorphisms, but further prospective studies are needed to establish clinical impact and cost-effectiveness.

Conclusions:

  • Pharmacogenetics and pharmacogenomics hold significant promise for tailoring medication therapy.
  • Personalized medicine, guided by genetic information, can lead to improved drug efficacy and enhanced patient safety.